Affimed N.V.: Fit-for-purpose ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND filing exp. by end of 3Q19 for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
Im Neuenheimer Feld 582
Heidelberg, 69120
Germany

Company Participants at Affimed KOL Event Dec 7

  • Adi Hoess, Ph.D., Chief Executive Officer
  • Florian Fischer, Ph.D., MBA, Chief Financial Officer
  • Gregory Gin, Head of Investor Relations

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.